Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
Takayuki Yoshino, Andrés Cervantes, Hideaki Bando, Erika Martinelli, Eiji Oki, Rui‐Hua Xu, Nadia Ayu Mulansari, K. Govind Babu, M.A. Lee, Cheng Tan, G. Cornelio, Dawn Q. Chong, Li‐Tzong Chen, Suebpong Tanasanvimon, Naiyarat Prasongsook, Kun‐Huei Yeh, C. Chua, Marie Dione Sacdalan, W.J. Sow, S.T. Kim, Raju Titus Chacko, Ridho Ardhi Syaiful, Shenshen Zhang, Giuseppe Curigliano, Saori Mishima, Yoshiaki Nakamura, Hiromichi Ebi, Yu Sunakawa, Masanobu Takahashi, Eishi Baba, Solange Peters, Chikashi Ishioka, G. Pentheroudakis
Abstract
•This article provides ESMO recommendations adapted for the treatment of metastatic colorectal cancer in Asian patients.•It outlines the diagnosis, staging, management, treatment and follow-up of patients with metastatic colorectal cancer.•An overview of the availability and reimbursement of certain tests and treatments is described for each Asian country.•The aim is to encourage evidence-based medicine and facilitate drug registration across the different countries of Asia. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries.